EU/3/20/2288

About

On 26 June 2020, orphan designation EU/3/20/2288 was granted by the European Commission to Granzer Regulatory Consulting & Services, Germany, for magrolimab for the treatment of myelodysplastic syndromes.

The sponsorship was transferred to Gilead Sciences Ireland UC, Ireland, in September 2020.

Key facts

Active substance
Magrolimab
Disease / condition
Treatment of myelodysplastic syndromes
Date of first decision
26/06/2020
Outcome
Positive
EU designation number
EU/3/20/2288

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Gilead Sciences Ireland UC
Ida Business & Technology Park
Carrigtohill T45 DP77
Ireland
E-mail: harley.besser@gilead.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating